Danny Nguyen

2.6k total citations · 1 hit paper
44 papers, 963 citations indexed

About

Danny Nguyen is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Danny Nguyen has authored 44 papers receiving a total of 963 indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Oncology, 35 papers in Pulmonary and Respiratory Medicine and 9 papers in Cancer Research. Recurrent topics in Danny Nguyen's work include Lung Cancer Treatments and Mutations (32 papers), Colorectal Cancer Treatments and Studies (20 papers) and Lung Cancer Research Studies (8 papers). Danny Nguyen is often cited by papers focused on Lung Cancer Treatments and Mutations (32 papers), Colorectal Cancer Treatments and Studies (20 papers) and Lung Cancer Research Studies (8 papers). Danny Nguyen collaborates with scholars based in United States, China and South Korea. Danny Nguyen's co-authors include Hongwei Wang, Fengdong Cheng, Eduardo M. Sotomayor, Kapil N. Bhalla, Peter Atadja, Edward Seto, Alejandro Villagra, Javier Pinilla‐Ibarz, Michelle Maurin and Kenneth L. Wright and has published in prestigious journals such as Journal of Clinical Oncology, Nature Immunology and PLoS ONE.

In The Last Decade

Danny Nguyen

40 papers receiving 939 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer

2021 196 citations Suresh S. Ramalingam, James Chih‐Hsin Yang et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Danny Nguyen United States	14	549	509	430	180	122	44	963
Brian Belmontes United States	13	421 0.8×	203 0.4×	322 0.7×	84 0.5×	169 1.4×	22	757
Hideki Terai Japan	15	297 0.5×	358 0.7×	480 1.1×	199 1.1×	36 0.3×	41	778
Yuho Maki Japan	17	382 0.7×	391 0.8×	633 1.5×	394 2.2×	72 0.6×	50	1.0k
Brian S. Henick United States	14	511 0.9×	308 0.6×	189 0.4×	141 0.8×	306 2.5×	57	854
Hideaki Mitsui Japan	18	320 0.6×	290 0.6×	393 0.9×	206 1.1×	69 0.6×	47	863
Alejandro Avilés‐Salas Mexico	14	369 0.7×	249 0.5×	295 0.7×	186 1.0×	81 0.7×	62	768
Si-Pei Wu China	13	941 1.7×	659 1.3×	544 1.3×	386 2.1×	300 2.5×	23	1.5k
R. Molife United Kingdom	11	291 0.5×	277 0.5×	300 0.7×	162 0.9×	54 0.4×	24	694
Jianchun Duan China	16	732 1.3×	367 0.7×	274 0.6×	146 0.8×	195 1.6×	59	1.1k
Sofia Genta Canada	12	434 0.8×	139 0.3×	289 0.7×	135 0.8×	170 1.4×	36	742

Countries citing papers authored by Danny Nguyen

Since Specialization

Citations

This map shows the geographic impact of Danny Nguyen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Danny Nguyen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Danny Nguyen more than expected).

Fields of papers citing papers by Danny Nguyen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Danny Nguyen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Danny Nguyen. The network helps show where Danny Nguyen may publish in the future.

Co-authorship network of co-authors of Danny Nguyen

This figure shows the co-authorship network connecting the top 25 collaborators of Danny Nguyen. A scholar is included among the top collaborators of Danny Nguyen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Danny Nguyen. Danny Nguyen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jänne, Pasi A., Bin-Chao Wang, Byoung Chul Cho, et al.. (2025). First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial. Journal of Clinical Oncology. 43(13). 1553–1563. 7 indexed citations

Norris, Mary K., Rebekah L. Wilson, Danny Nguyen, et al.. (2025). Resistance exercise combined with protein supplementation for skeletal muscle mass in people with pancreatic cancer undergoing neoadjuvant chemotherapy: Study protocol for the REBUILD trial. PLoS ONE. 20(5). e0322192–e0322192. 2 indexed citations

Mambetsariev, Isa, et al.. (2025). Current paradigm of EGFR in non-small cell lung cancer: A long way forward. Med. 6(9). 100803–100803.

Nguyen, Danny & Edgardo S. Santos. (2025). Dermatologic Adverse Event Mitigation and Management Strategies with Amivantamab + Lazertinib Therapy for Advanced Non-Small Cell Lung Cancer: A Vodcast. Targeted Oncology. 20(5). 737–742.

Lee, SH, Shun Lü, Daniil Stroyakovskiy, et al.. (2024). LBA55 Mechanisms of acquired resistance to first-line amivantamab plus lazertinib versus osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: An early analysis from the phase III MARIPOSA study. Annals of Oncology. 35. S1245–S1246. 19 indexed citations

Loo, A. Van, et al.. (2024). Role of CD44 in Chemotherapy Treatment Outcome: A Scoping Review of Clinical Studies. International Journal of Molecular Sciences. 25(6). 3141–3141. 6 indexed citations

Ou, Sai‐Hong Ignatius, Huamao Mark Lin, Jin‐Liern Hong, et al.. (2023). Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison. Lung Cancer. 179. 107186–107186. 4 indexed citations

Ou, Sai‐Hong Ignatius, Huamao Mark Lin, Jin‐Liern Hong, et al.. (2023). Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion Mutations. JTO Clinical and Research Reports. 4(10). 100558–100558. 25 indexed citations

Crook, Christiana, et al.. (2023). Proposed Implementation of a Patient-Centered Self-Assessment Tool for Patients with Neuroendocrine Tumors among Academic and Community Practice Sites: The City of Hope Model. Journal of Clinical Medicine. 12(3). 1229–1229.

10.

Curioni‐Fontecedro, Alessandra, M. Frueh, David König, et al.. (2023). 1412P SAKK 17/18-ORIGIN trial: Efficacy and safety from a multicenter phase II trial of gemcitabine and atezolizumab in patients with advanced NSCLC progressing on immune checkpoint inhibitors. Annals of Oncology. 34. S807–S808. 1 indexed citations

11.

Kang, Dong‐Woo, Rebekah L. Wilson, Mary K. Norris, et al.. (2022). Targeting Adiposity and Inflammation With Movement to Improve Prognosis in Breast Cancer Survivors (The AIM Trial): Rationale, Design, and Methods. Frontiers in Oncology. 12. 896995–896995. 1 indexed citations

12.

Ramalingam, Suresh S., S-W. Kim, Gregory J. Riely, et al.. (2021). 1231P Characterization and management of mobocertinib (TAK-788) induced skin toxicity in patients with EGFR exon 20 insertion+ (ex20ins+) non-small cell lung cancer (NSCLC) who previously received platinum chemotherapy. Annals of Oncology. 32. S975–S975. 1 indexed citations

13.

Ou, S-H.I., Huamao Mark Lin, Yuping Yin, et al.. (2021). 1211P Indirect comparison of mobocertinib and standard of care in platinum-pretreated patients with NSCLC with EGFR exon 20 insertion. Annals of Oncology. 32. S964–S965. 2 indexed citations

14.

Zhou, C., Suresh S. Ramalingam, Jian Fang, et al.. (2021). OA04.03 Mobocertinib in NSCLC With EGFR Exon 20 Insertions: Results From EXCLAIM and Pooled Platinum-Pretreated Patient Populations. Journal of Thoracic Oncology. 16(3). S108–S108. 21 indexed citations

15.

Page, Stacey, et al.. (2020). How Semantics Connotations May Influence Concerns About Donation of Biospecimens. Biopreservation and Biobanking. 19(3). 156–162. 1 indexed citations

16.

Piotrowska, Zofia, Danny Nguyen, Marianna Koczywas, et al.. (2020). 1345P Preliminary safety and activity of CLN-081 in NSCLC with EGFR exon 20 insertion mutations (Ins20). Annals of Oncology. 31. S862–S863. 9 indexed citations

17.

Dhindsa, Banreet, et al.. (2020). Utility of inflammatory markers to predict adverse outcome in acute pancreatitis: A retrospective study in a single academic center. Saudi Journal of Gastroenterology. 26(4). 216–216. 9 indexed citations

18.

Jänne, Pasi A., Yi‐Long Wu, Terufumi Kato, et al.. (2020). 1412TiP Mobocertinib (TAK-788) as first-line treatment vs platinum-based chemotherapy (CT) for NSCLC with EGFR exon 20 insertions (exon20ins). Annals of Oncology. 31. S892–S893. 5 indexed citations

19.

Liu, Stephen V., Liza C. Villaruz, Victor Lee, et al.. (2020). LBA61 First analysis of RAIN-701: Study of tarloxotinib in patients with non-small cell lung cancer (NSCLC) EGFR Exon 20 insertion, HER2-activating mutations & other solid tumours with NRG1/ERBB gene fusions. Annals of Oncology. 31. S1189–S1189. 61 indexed citations

20.

Villagra, Alejandro, Fengdong Cheng, Hongwei Wang, et al.. (2008). The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nature Immunology. 10(1). 92–100. 355 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact